Compare GoPro Inc (GPRO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Neurocrine Biosciences Inc — how do they compare? GoPro Inc trades at $0.67 (market cap $122.03M), while Neurocrine Biosciences Inc trades at $171.61 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is far larger — about 141.8× GoPro Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| GPRO | NBIX | |
|---|---|---|
Market Cap | $122.03M | $17.30B |
Sector | Technology | Health |
52-Week High | $2.88 | $180.55 |
52-Week Low | $0.64 | $123.10 |
Enterprise Value | $169.98M | $16.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $0.6978, down 1.86% on the day, reflecting persistent bearish sentiment amid financial distress. The stock shows a negative technical trend with recent earnings misses and declining revenues. The company is undergoing a strategic review for a potential sale or merger, with the CEO providing $20 million in financing to support operations. Valuation ratios like P/E of 4.56 and P/S of 0.18 appear low, but profitability remains deeply negative with a net income margin of -20.7% and ROE of -236.05%.
The outlook is highly speculative, hinging on the success of the strategic review; a sale could unlock value, but ongoing cash burn and competitive pressures pose significant risks. Investors face a binary outcome: potential upside from a strategic transaction versus substantial downside if the company fails to stabilize.
Neurocrine Biosciences (NBIX) trades at $171.81, down slightly by 0.1% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, and robust profitability metrics like a 98.17% gross margin. Recent news highlights pipeline advancements and a Zacks upgrade to Strong Buy, reflecting positive sentiment.
Outlook remains positive with a consensus price target of $195.75, implying 14% upside. Key opportunities include sustained revenue growth and pipeline progress, while risks involve execution on recent acquisitions and competitive pressures. The stock is well-positioned for momentum but requires monitoring of Q2 2026 results due July 30.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
